Volume 10 Supplement 2

Breast Cancer Research 2008

Open Access

MCPH1, a potential predictor for response to cancer chemotherapy

  • SM Bell1,
  • V Speirs1 and
  • EE Morrison1
Breast Cancer Research200810(Suppl 2):P58

https://doi.org/10.1186/bcr1942

Published: 13 May 2008

Background

We previously identified MCPH1, a DNA damage response protein involved in the regulation of the breast cancer tumour suppressor gene BRCA1, as the defective protein in one form of microcephaly [1]. We found that reduced expression of MCPH1 causes premature chromosome condensation (PCC) [2]. PCC is a hallmark of mammalian cells that begin mitosis before completing DNA replication. The MCPH1 locus (8p22-p23) is frequently deleted in many tumour types and this is associated with a poor prognosis and a reduced response to chemotherapy in breast cancer [3]. Many chemotherapeutic agents such as taxanes (for example, Taxol) require a functional spindle checkpoint for the induction of apoptosis in cancer cells.

Methods

Using time-lapse imaging we have studied mitotic progression in MCPH1-deficient cells. The presence of a functional spindle assembly checkpoint was tested for using two different spindle poisons – for example, Taxol and nocodazole – in MCPH1-deficient cells. Immunohistochemistry using a MCPH1 antibody was performed on 54 breast cancer samples and was correlated with pathology data.

Results

We have identified a number of mitotic defects including slower mitotic progression displaying aberrant chromosomal congression and micronuclei formation in MCPH1-deficient cells. MCPH1-deficient cells displayed a reduced mitotic arrest in response to spindle poisons, indicating impairment of the spindle checkpoint. Our immunohistochemistry data have identified reduced MCPH1 expression in 32% (17/54) of breast cancers, particularly in higher grade tumours.

Conclusion

The mitotic phenotype suggests that loss of MCPH1 function in tumours could cause mitotic errors resulting in aneuploidy development. Our data indicate MCPH1 plays a role in resistance to chemotherapeutic agents such as Taxol through its involvement in the spindle checkpoint and apoptosis. We therefore hypothesise that, while germline defects in MCPH1 cause microcephaly, somatic defects may cause aneuploidy development and resistance to chemotherapy in breast cancer.

Declarations

Acknowledgements

Supported by Yorkshire Cancer Research.

Authors’ Affiliations

(1)
Leeds Institute for Molecular Medicine, University of Leeds, Wellcome Trust Brenner Building, St James's University Hospital

References

  1. Jackson AP, Eastwood H, Bell SM, Adu J, Toomes C, Carr IM, Roberts E, Hampshire DJ, Crow YJ, Mighell AJ, Karbani G, Jafri H, Rashid Y, Muller RF, Markham AF, Woods CG: Identification of Microcephalin, a protein implicated in determining the size of the human brain. Am J Hum Genet. 2002, 71: 136-142. 10.1086/341283.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Trimborn M, Bell SM, Felix C, Rashid Y, Jafri H, Griffiths PD, Neumann LM, Krebs A, Reis A, Sperling K, Neitzel H, Jackson AP: Mutations in microcephalin cause aberrant regulation of chromosome condensation. Am J Hum Genet. 2004, 75: 261-266. 10.1086/422855.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Tsuneizumi M, Emi M, Hirano A, Utada Y, Tsumagari K, Takahashi K, Kasumi F, Akiyama F, Sakamoto G, Kazui T, Nakamura Y: Association of allelic loss at 8p22 with poor prognosis among breast cancer cases treated with high-dose adjuvant chemotherapy. Cancer Lett. 2004, 180: 75-82. 10.1016/S0304-3835(02)00010-1.View ArticleGoogle Scholar

Copyright

© BioMed Central Ltd 2008

Advertisement